{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:35:11Z","timestamp":1794897311238,"version":"4.9.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR002344"],"award-info":[{"award-number":["TL1TR002344"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002345"],"award-info":[{"award-number":["UL1TR002345"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA199092"],"award-info":[{"award-number":["U54CA199092"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA094056"],"award-info":[{"award-number":["P50CA094056"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA091842"],"award-info":[{"award-number":["P30CA091842"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug resistance and dose-limiting toxicities are significant barriers for treatment of multiple myeloma (MM). Bone marrow microenvironment (BMME) plays a major role in drug resistance in MM. Drug delivery with targeted nanoparticles have been shown to improve specificity and efficacy and reduce toxicity. We aim to improve treatments for MM by (1) using nanoparticle delivery to enhance efficacy and reduce toxicity; (2) targeting the tumor-associated endothelium for specific delivery of the cargo to the tumor area, and (3) synchronizing the delivery of chemotherapy (bortezomib; BTZ) and BMME-disrupting agents (ROCK inhibitor) to overcome BMME-induced drug resistance. We find that targeting the BMME with P-selectin glycoprotein ligand-1 (PSGL-1)-targeted BTZ and ROCK inhibitor-loaded liposomes is more effective than free drugs, non-targeted liposomes, and single-agent controls and reduces severe BTZ-associated side effects. These results support the use of PSGL-1-targeted multi-drug and even non-targeted liposomal BTZ formulations for the enhancement of patient outcome in MM.<\/jats:p>","DOI":"10.1038\/s41467-020-19932-1","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T11:03:24Z","timestamp":1606475004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma"],"prefix":"10.1038","volume":"11","author":[{"given":"Cinzia","family":"Federico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-0357","authenticated-orcid":false,"given":"Kinan","family":"Alhallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feda","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail P.","family":"Sudlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"de la Puente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Muz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-1487","authenticated-orcid":false,"given":"Vaishali","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4228-194X","authenticated-orcid":false,"given":"Matea","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kotsybar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Wasden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-4775","authenticated-orcid":false,"given":"Nicole","family":"Guenthner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Gurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kohnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6329-952X","authenticated-orcid":false,"given":"Noha N.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Thotala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis E.","family":"Hallahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3133-6717","authenticated-orcid":false,"given":"Samuel","family":"Achilefu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-2780","authenticated-orcid":false,"given":"Abdel Kareem","family":"Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"19932_CR1","first-page":"271","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller, K. D. et al. Cancer treatment and survivorship statistics, 2016. CA: Cancer J. Clin. 66, 271\u2013289 (2016).","journal-title":"CA: Cancer J. Clin."},{"key":"19932_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2217\/fon-2016-0200","volume":"13","author":"WI Gonsalves","year":"2017","unstructured":"Gonsalves, W. I., Milani, P., Derudas, D. & Buadi, F. K. The next generation of novel therapies for the management of relapsed multiple myeloma. Future Oncol. 13, 63\u201375 (2017).","journal-title":"Future Oncol."},{"key":"19932_CR3","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/bmt.2016.91","volume":"51","author":"W Gonsalves","year":"2016","unstructured":"Gonsalves, W. et al. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy. Bone Marrow Transplant. 51, 1156 (2016).","journal-title":"Bone Marrow Transplant."},{"key":"19932_CR4","doi-asserted-by":"publisher","unstructured":"de la Puente, P., Muz, B., Azab, F., Luderer, M. & Azab, A. K. Molecularly targeted therapies in multiple myeloma. Leuk. Res. Treatment 2014 https:\/\/doi.org\/10.1155\/2014\/976567 (2014).","DOI":"10.1155\/2014\/976567"},{"key":"19932_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1182\/blood-2009-01-199281","volume":"114","author":"AK Azab","year":"2009","unstructured":"Azab, A. K. et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 114, 619\u2013629 (2009).","journal-title":"Blood"},{"key":"19932_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood-2009-05-218214","volume":"114","author":"AK Azab","year":"2009","unstructured":"Azab, A. K. & Ghobrial, I. M. Response: sensitization initiated. Blood 114, 926\u2013927 (2009).","journal-title":"Blood"},{"key":"19932_CR7","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","volume":"119","author":"AK Azab","year":"2012","unstructured":"Azab, A. K. et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood 119, 1468\u20131478 (2012).","journal-title":"Blood"},{"key":"19932_CR8","doi-asserted-by":"publisher","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","volume":"113","author":"AK Azab","year":"2009","unstructured":"Azab, A. K. et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 113, 4341\u20134351 (2009).","journal-title":"Blood"},{"key":"19932_CR9","doi-asserted-by":"publisher","unstructured":"Muz, B. et al. Inhibition of P-selectin and PSGL-1 using humanized monoclonal antibodies increases the sensitivity of multiple myeloma cells to bortezomib. BioMed Res. Int. 2015, https:\/\/doi.org\/10.1155\/2015\/417586 (2015).","DOI":"10.1155\/2015\/417586"},{"key":"19932_CR10","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson, P. G. et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 27, 3518\u20133525 (2009).","journal-title":"J. Clin. Oncol."},{"key":"19932_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1345\/aph.1R561","volume":"47","author":"JL Thompson","year":"2013","unstructured":"Thompson, J. L. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma. Ann. Pharmacother. 47, 56\u201362, https:\/\/doi.org\/10.1345\/aph.1R561 (2013).","journal-title":"Ann. Pharmacother."},{"key":"19932_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature09339","volume":"467","author":"JS de Bono","year":"2010","unstructured":"de Bono, J. S. & Ashworth, A. Translating cancer research into targeted therapeutics. Nature 467, 543\u2013549 (2010).","journal-title":"Nature"},{"key":"19932_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/ejh.12870","volume":"98","author":"P de la Puente","year":"2017","unstructured":"de la Puente, P. & Azab, A. K. Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma. Eur. J. Haematol. 98, 529\u2013541 (2017).","journal-title":"Eur. J. Haematol."},{"key":"19932_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jconrel.2017.11.045","volume":"270","author":"P de la Puente","year":"2017","unstructured":"de la Puente, P. et al. Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma. J. Control Release 270, 158\u2013176 (2017).","journal-title":"J. Control Release"},{"key":"19932_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.biomaterials.2015.09.017","volume":"73","author":"P de la Puente","year":"2015","unstructured":"de la Puente, P. et al. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials 73, 70\u201384 (2015).","journal-title":"Biomaterials"},{"key":"19932_CR16","doi-asserted-by":"publisher","unstructured":"Manier, S., Sacco, A., Leleu, X., Ghobrial, I. & Roccaro, A. M. Bone marrow microenvironment in multiple myeloma progression. BioMed Res. Int. 2012 https:\/\/doi.org\/10.1155\/2012\/157496 (2012).","DOI":"10.1155\/2012\/157496"},{"key":"19932_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1081\/CNV-120030218","volume":"22","author":"J Adams","year":"2004","unstructured":"Adams, J. & Kauffman, M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest. 22, 304\u2013311 (2004).","journal-title":"Cancer Invest."},{"key":"19932_CR18","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","volume":"17","author":"S Arastu-Kapur","year":"2011","unstructured":"Arastu-Kapur, S. et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin. Cancer Res. 17, 2734\u20132743 (2011).","journal-title":"Clin. Cancer Res."},{"key":"19932_CR19","doi-asserted-by":"crossref","unstructured":"Detappe, A., Bustoros, M., Mouhieddine, T. H. & Ghoroghchian, P. P. Advancements in nanomedicine for multiple myeloma. Trend. Mol. Med. 24, 560\u2013574 (2018).","DOI":"10.1016\/j.molmed.2018.04.005"},{"key":"19932_CR20","doi-asserted-by":"publisher","first-page":"e25281","DOI":"10.7554\/eLife.25281","volume":"6","author":"S Ferber","year":"2017","unstructured":"Ferber, S. et al. Co-targeting the tumor endothelium and P-selectin-expressing glioblastoma cells leads to a remarkable therapeutic outcome. Elife 6, e25281 (2017).","journal-title":"Elife"},{"key":"19932_CR21","doi-asserted-by":"publisher","first-page":"345ra387","DOI":"10.1126\/scitranslmed.aaf7374","volume":"8","author":"Y Shamay","year":"2016","unstructured":"Shamay, Y. et al. P-selectin is a nanotherapeutic delivery target in the tumor microenvironment. Sci. Transl. Med. 8, 345ra387 (2016).","journal-title":"Sci. Transl. Med."},{"key":"19932_CR22","doi-asserted-by":"crossref","unstructured":"Ghobrial, I. M. et al. Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma. Am. J. Hematol. 19, 1244\u20131253 (2019).","DOI":"10.1002\/ajh.25627"},{"key":"19932_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bbmt.2008.10.018","volume":"15","author":"DA Stewart","year":"2009","unstructured":"Stewart, D. A., Smith, C., MacFarland, R. & Calandra, G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol. Blood Marrow Transplant. 15, 39\u201346 (2009).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"19932_CR24","first-page":"14","volume":"18","author":"R Schwartz","year":"2004","unstructured":"Schwartz, R. & Davidson, T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology 18, 14\u201321 (2004).","journal-title":"Oncology"},{"key":"19932_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1158\/0008-5472.CAN-05-1195","volume":"66","author":"AM Roccaro","year":"2006","unstructured":"Roccaro, A. M. et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66, 184\u2013191 (2006).","journal-title":"Cancer Res."},{"key":"19932_CR26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1349-7006.2010.01544.x","volume":"101","author":"D Tamura","year":"2010","unstructured":"Tamura, D. et al. Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2\/M transition. Cancer Sci. 101, 1403\u20131408 (2010).","journal-title":"Cancer Sci."},{"key":"19932_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/15384047.2019.1665405","volume":"21","author":"B Muz","year":"2020","unstructured":"Muz, B. et al. CXCR4-targeted PET imaging using (64)Cu-AMD3100 for detection of Waldenstr\u00f6m Macroglobulinemia. Cancer Biol. Ther. 21, 52\u201360 (2020).","journal-title":"Cancer Biol. Ther."},{"key":"19932_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/978-1-4939-1619-1_8","volume":"1226","author":"C Idleburg","year":"2015","unstructured":"Idleburg, C., DeLassus, E. N. & Novack, D. V. Immunohistochemistry of skeletal tissues. Methods Mol. Biol. 1226, 87\u201395 (2015).","journal-title":"Methods Mol. Biol."},{"key":"19932_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11095-019-2670-z","volume":"36","author":"MJ Luderer","year":"2019","unstructured":"Luderer, M. J. et al. Thermal sensitive liposomes improve delivery of boronated agents for boron neutron capture therapy. Pharm. Res. 36, 144 (2019).","journal-title":"Pharm. Res."},{"key":"19932_CR30","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s11095-011-0430-9","volume":"28","author":"MM van Beuge","year":"2011","unstructured":"van Beuge, M. M. et al. Increased liver uptake and reduced hepatic stellate cell activation with a cell-specific conjugate of the Rho-kinase inhibitor Y27632. Pharm. Res. 28, 2045\u20132054 (2011).","journal-title":"Pharm. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19932-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T02:13:00Z","timestamp":1670292780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19932-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["19932"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-19932-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"5 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K.A. and C.F. have filed a patent with regards to the technology described in this study. A.K.A. is the founder and owner of Targeted Therapeutics LLC and Cellatrix LLC; however, the aforementioned entities did not contribute to the current study. Other authors state no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6037"}}